FLT3 and acute myeloid leukemia: While FLT3 mutations alone are not recommended as targets for sequential monitoring due to their instability [11], many patients with FLT3 mutated AML have a co-existing stable genetic lesion suitable for molecular monitoring including NPM1 mutation (mut) or fusion genes (FG).